PMID- 28571536
OWN - NLM
STAT- MEDLINE
DCOM- 20191016
LR  - 20191016
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 19
IP  - 6
DP  - 2018
TI  - AMP-activated Protein Kinase as a Drug Target in Chronic Kidney Disease.
PG  - 709-720
LID - 10.2174/1389450118666170601130947 [doi]
AB  - BACKGROUND: Chronic kidney disease (CKD) is a condition increasingly affecting 
      millions of individuals worldwide and is ranked as the ninth leading cause of 
      death in the United States. AMPactivated protein kinase (AMPK) is an energy 
      sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK 
      activity and autophagic signaling, and sustained activation of mammalian target 
      of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been 
      shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell 
      apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as 
      a modulator of the aforementioned pathways that underpin the pathophysiology of 
      CKD. Furthermore, pharmacological activators of AMPK such as metformin have been 
      shown to exert renoprotective effects in experimental studies and improve 
      clinical outcomes in patients with CKD. OBJECTIVE: The current review focuses on 
      the nephroprotective effects of AMPK and its utility as a therapeutic target for 
      the prevention and treatment of CKD.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Allouch, Soumaya
AU  - Allouch S
AD  - College of Pharmacy, Qatar University, PO Box 2713, Doha, Qatar.
FAU - Munusamy, Shankar
AU  - Munusamy S
AD  - College of Pharmacy, Qatar University, PO Box 2713, Doha, Qatar.
AD  - College of Pharmacy and Health Sciences, Drake University, Des Moines, Iowa, IA 
      50311-3010, United States.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Autophagy/drug effects
MH  - Endoplasmic Reticulum Stress/drug effects
MH  - Epithelial-Mesenchymal Transition
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Renal Insufficiency, Chronic/*drug therapy/enzymology/physiopathology
OTO - NOTNLM
OT  - AMP-activated protein kinase
OT  - apoptosis
OT  - autophagy
OT  - chronic kidney disease
OT  - endoplasmic reticulum stress
OT  - epithelial- mesenchymal transition
OT  - mammalian target of rapamycin
OT  - metformin.
EDAT- 2017/06/03 06:00
MHDA- 2019/10/17 06:00
CRDT- 2017/06/03 06:00
PHST- 2017/03/11 00:00 [received]
PHST- 2017/05/17 00:00 [revised]
PHST- 2017/05/26 00:00 [accepted]
PHST- 2017/06/03 06:00 [pubmed]
PHST- 2019/10/17 06:00 [medline]
PHST- 2017/06/03 06:00 [entrez]
AID - CDT-EPUB-83839 [pii]
AID - 10.2174/1389450118666170601130947 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2018;19(6):709-720. doi: 10.2174/1389450118666170601130947.